{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-272860","form_type":"8-K","ticker":"BEAM","cik":"0001745999","company_name":"Beam Therapeutics Inc.","filed_at":"2024-12-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.440850+00:00","generated_at":"2026-05-29T05:43:27.168374+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Beam reports BEAM-101 Phase 1/2 data: all 7 patients achieved >60% HbF, resolved anemia; ESCAPE proof-of-concept in NHPs","bullets":["Seven patients dosed with BEAM-101 achieved HbF >60%, HbS <40%, and resolution of anemia; no VOCs post-engraftment.","Mean neutrophil engraftment 17.1 days, platelet 19.1 days; one death from busulfan-related respiratory failure deemed unrelated.","ESCAPE antibody conditioning in NHPs enabled long-term engraftment of base-edited HSCs with >80% HbF-containing cells.","BEAM-103 mAb dosing was well tolerated without transfusions or supportive care; minor declines in neutrophils/platelets.","BEAM-302 initial clinical data from multiple cohorts now expected in first half of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-272860","json":"https://secwatch.observer/filing/0001193125-24-272860.json","markdown":"https://secwatch.observer/filing/0001193125-24-272860.md","text":"https://secwatch.observer/filing/0001193125-24-272860.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1745999/000119312524272860/0001193125-24-272860-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1745999/000119312524272860/d903914d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T05:43:27.168374+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}